2,4-Bis-(dimethylamino)-6-methylpyrimidin | 7471-62-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,4-Bis-(dimethylamino)-6-methylpyrimidin
• 英文别名: 2,4-Bis-dimethylamino-6-methylpyrimidine；2,4-Bis(dimethylamino)-6-methylpyrimidine；2-N,2-N,4-N,4-N,6-pentamethylpyrimidine-2,4-diamine
• CAS: 7471-62-7
• 化学式: C₉H₁₆N₄
• 分子量: 180.253
• InChiKey: CLUPKZJSRWUNHD-UHFFFAOYSA-N

物化性质

• 熔点：
  131-132 °C(Solv: hexane (110-54-3))
• 沸点：
  132 °C(Press: 11 Torr)
• 密度：
  1.072±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  在 四氯化钛 作用下， 以 乙醚 、 苯 为溶剂， 反应 1.5h， 生成 2,4-Bis-(dimethylamino)-6-methylpyrimidin
  参考文献：
  名称：

  Syntheses of 2,4-Diaminopyrimidines and 1-Aminoisoquinolines in the Reactions of Alkyl and Benzyl Ketones with Cyanamide and N,N-dimethylcyanamide

  摘要：

  The reaction of alkyl and benzyl ketones with cyanamide and N,N-dimethylcyanamide in the presence of POCl3 was examined. At the first stage, chloroformamidine derivatives were formed. In the presence of TiCl4, they underwent further reactions to the derivatives of 1-aminoisoquinoline and 2,4-diaminopyrimidine. The effect of a constitution of substrates on adequate ratios of heterocyclic compounds is discussed.

  DOI：

  10.3987/com-93-6583

文献信息

• TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER
  申请人：THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

  公开号：US20160229811A1

  公开（公告）日：2016-08-11

  The present disclosure provides tetra-substituted cyclobutane inhibitors of Androgen Receptor Action, and methods of using such inhibitors, for the treatment of hormone-refractory cancers.

  本公开提供了四取代环丁烷抑制剂的雄激素受体作用，并使用这些抑制剂的方法，用于治疗激素难治性癌症。
• [EN] TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER<br/>[FR] INHIBITEURS TÉTRA-ARYLE-CYCLOBUTANE DE L'ACTION DU RÉCEPTEUR DES ANDROGÈNES POUR LE TRAITEMENT D'UN CANCER RÉFRACTAIRE AUX HORMONES
  申请人：UNIV ILLINOIS

  公开号：WO2015048246A1

  公开（公告）日：2015-04-02

  The present disclosure provides tetra-substituted cyclobutane inhibitors of Androgen Receptor Action, and methods of using such inhibitors, for the treatment of hormone-refractory cancers.

  本公开提供了四取代环丁烷抑制剂，用于雄激素受体作用的抑制剂，并提供了使用这些抑制剂治疗激素难治性癌症的方法。
• 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors
  申请人：Ennis Michael Dalton

  公开号：US20080176857A1

  公开（公告）日：2008-07-24

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , X 4 , X 6 , R 2 , R 4 , R 5 , and R 6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药物可接受的盐，其中化合物具有公式I的结构：其中A1、A2、A3、A4、A5、A6、A7、A8、X4、X6、R2、R4、R5和R6如本发明详细描述中所定义。本发明还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• Alicyclic Heterocyclic Compound
  申请人：Furukubo Shigeru

  公开号：US20090182140A1

  公开（公告）日：2009-07-16

  An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P 1 and P 2 are CH or N, q and r are 0 to 2, X is —NH—, —O—, —CH 2 —, etc., Y is —CH 2 —, —CO—, —SO 2 —, etc., Z is —CO—, —SO 2 —, etc., and R 3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR 4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

  以下式子所示的脂环杂环化合物或其药学上可接受的盐： 其中环A为杂环，环B为碳环，杂环等，P1和P2为CH或N，q和r为0至2，X为—NH—，—O—，—CH2—等，Y为— —，—CO—，—SO2—等，Z为—CO—，—SO2—等，R3为碳环基团，杂环基团，羟基，烷氧基或氨基，用作CCR4功能调节剂，用于预防或治疗支气管哮喘，特应性皮炎等。
• Pfleiderer; Mosthaf, Chemische Berichte, 1957, vol. 90, p. 738,745
  作者：Pfleiderer、Mosthaf

  DOI：——

  日期：——